These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 37394562)
1. Persistent increase and improved survival of stage I lung cancer based on a large-scale real-world sample of 26,226 cases. Wang C; Shao J; Song L; Ren P; Liu D; Li W Chin Med J (Engl); 2023 Aug; 136(16):1937-1948. PubMed ID: 37394562 [TBL] [Abstract][Full Text] [Related]
2. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification. Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800 [TBL] [Abstract][Full Text] [Related]
3. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system]. Gao J; Chen JQ; Zhang L; Liang ZY Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304 [TBL] [Abstract][Full Text] [Related]
4. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862 [TBL] [Abstract][Full Text] [Related]
5. [Current status of postoperative pathological diagnosis of lung cancer in China: a multicenter big data study]. ; Zhonghua Bing Li Xue Za Zhi; 2021 Aug; 50(8):882-890. PubMed ID: 34344071 [No Abstract] [Full Text] [Related]
6. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355 [TBL] [Abstract][Full Text] [Related]
8. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205 [TBL] [Abstract][Full Text] [Related]
9. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530 [TBL] [Abstract][Full Text] [Related]
10. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967 [TBL] [Abstract][Full Text] [Related]
11. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H J Cancer Res Clin Oncol; 2016 Apr; 142(4):833-43. PubMed ID: 26646246 [TBL] [Abstract][Full Text] [Related]
13. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL Oncology; 2015; 89(3):175-86. PubMed ID: 25833149 [TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432 [TBL] [Abstract][Full Text] [Related]
15. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151 [TBL] [Abstract][Full Text] [Related]
16. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas. Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177 [TBL] [Abstract][Full Text] [Related]
17. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442 [TBL] [Abstract][Full Text] [Related]
18. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518 [TBL] [Abstract][Full Text] [Related]
19. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169 [TBL] [Abstract][Full Text] [Related]
20. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. Hondelink LM; Ernst SM; Atmodimedjo P; Cohen D; Wolf JL; Dingemans AC; Dubbink HJ; von der Thüsen JH Eur J Cancer; 2023 Mar; 181():53-61. PubMed ID: 36638752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]